Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis

Exclusion Criteria

• •Patients with autoimmune gastritis (chronic atrophic gastritis type A), peptic ulcer (a1-h2), reflux esophagitis, gastric polyps, hypertrophic gastritis and other diseases;
• •Patients with high-grade intraepithelial neoplasia of gastric mucosa, suspected malignant change of gastrointestinal mucosal lesions, and gastrointestinal tumors;
• •Patients with malignant tumors who have undergone surgery, radiotherapy and chemotherapy in recent 5 years;
• •Patients with primary diseases such as heart, brain, lung, hematopoietic system and malignant tumors, and subjects with severe diabetes;
• •Patients with chronic liver and kidney dysfunction before treatment, including ALT \> 1.5 times the upper limit of normal value, blood creatinine (CR) \> 1.5 times the upper limit of normal value, and platelets lower than 1.5 times the lower limit of normal value;
• •Disabled subjects specified by law (blind, deaf, dumb, intellectual, mental, physical disabilities);
• •The description of self symptoms is unclear or the investigation is not the author;
• •Have a history of alcohol abuse;
• •Allergic constitution or a history of allergy to multiple drugs (more than two or known ingredients in the drug);
• •Pregnant or lactating women;
• •According to the judgment of the researcher, other reasons should not be selected.